Nicolas Sergeant

Nicolas Sergeant, a distinguished Research Director at Inserm UMRS1172 in Lille, France, brings over three decades of expertise in neurodegenerative diseases, with a particular focus on Alzheimer’s disease, tauopathies, and other neurodegenerative disorders. His current role involves leading cutting-edge research initiatives aimed at deciphering the complex molecular mechanisms underlying neurodegeneration, with an emphasis on biomarker discovery, physiopathology, and therapeutic target identification. At Inserm, Nicolas oversees multidisciplinary projects that integrate proteomics, biochemistry, and clinical research to develop innovative diagnostic tools and therapeutic strategies.

One of his key contributions is his leadership in the validation and industrialization of biomarkers, exemplified by the development of the 4MID(r) Kits, which facilitate early diagnosis and disease monitoring. His work spans the entire translational pipeline—from initial discovery in the laboratory to clinical validation and industrial deployment—ensuring that scientific breakthroughs translate into tangible benefits for patients. Nicolas’s expertise in proteomics and physiopathology has been instrumental in identifying novel therapeutic targets, advancing personalized medicine approaches in neurodegenerative diseases.

As a co-founder of SPQI-4BioDx, Nicolas has also demonstrated a strong commitment to biotech innovation and biomarker valorization, bridging academic research with industry. His scientific leadership is complemented by his skills in clinical research, diagnostics, and biotechnologies, positioning him at the forefront of neurodegenerative disease research and biomarker development. Through his work, Nicolas Sergeant continues to contribute significantly to the understanding and treatment of debilitating neurodegenerative conditions, fostering new avenues for diagnosis and therapy.